ResearcherJohns Hopkins UniversityActive in the last 2 years
Amanda L. Huff
Matched on ORCID iD 0000-0002-8423-8985; OpenAlex author ID A5022285180; NIH RePORTER profile ID 15766467. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 35
2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 grant · 2026: 4 papers
Papers 5
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
- Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. First author DOI 10.1158/2159-8290.cd-25-2245↗
- A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. First author DOI 10.1158/2326-6066.cir-25-0545↗
- Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
Grants 1
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elizabeth M. Jaffee · 5 shared papers, 2021–2026 · strength 0.91
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Won Jin Ho · 5 shared papers, 2021–2026 · strength 0.91
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Hao Wang · 4 shared papers, 2026 · strength 0.81
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Katherine M. Bever · 4 shared papers, 2026 · strength 0.81
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Marina Baretti · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Luciane Tsukamoto Kagohara · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Mark M. Yarchoan · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Neeha Zaidi · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Nilofer Saba Azad · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Jae Woo Lee · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Robert A. Anders · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Elana Judith Fertig · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Janelle Marie Montagne · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Daniel A. Laheru · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
- Jacob T. Mitchell · 1 shared paper, 2026 · strength 0.23
- Dung Thi Le · 1 shared paper, 2026 · strength 0.23
- Dimitrios N. Sidiropoulos · 1 shared paper, 2026 · strength 0.21
- Takeichi Yoshida · 1 shared paper, 2026 · strength 0.21
- Matthew Z. Guo · 1 shared paper, 2026 · strength 0.21
- Hassan Sinan · 1 shared paper, 2026 · strength 0.21
- Elizabeth Abou Diwan · 1 shared paper, 2026 · strength 0.21
- Michael Goggins · 1 shared paper, 2026 · strength 0.21
- Linda Chi Hang Chu · 1 shared paper, 2026 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.